{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:17:24Z","timestamp":1793787444074,"version":"4.6.1"},"reference-count":253,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1053,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1186\/s13613-023-01153-6","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T04:02:30Z","timestamp":1689652950000},"page":"65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients"],"prefix":"10.1016","volume":"13","author":[{"given":"Fran\u00e7ois","family":"Barbier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Hraiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solen","family":"Kern\u00e9is","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathana\u00ebl","family":"Veluppillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Pajot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Poissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ralph","family":"Zahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0010","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0015","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajic.2019.08.023","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012\u20132017: Device-associated module","volume":"48","author":"Rosenthal","year":"2020","journal-title":"Am J Infect Control"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0030","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10096-019-03673-1","article-title":"Resistance reported from China antimicrobial surveillance network (CHINET) in 2018","volume":"38","author":"Hu","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.022","article-title":"In-vitro activity of imipenem\/relebactam and key \u03b2-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015\u20132017","volume":"55","author":"Karlowsky","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01153-6_bb0040","unstructured":"Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019 [Internet]. Centers for Disease Control and Prevention (U.S.); 2019. https:\/\/stacks.cdc.gov\/view\/cdc\/82532. Accessed 26 Mar 2023."},{"key":"10.1186\/s13613-023-01153-6_bb0045","unstructured":"Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual epidemiological report for 2021. European Centre for Disease Prevention and Control. Available at www.ecdc.europa.eu. Accessed 15 Jan 2023."},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/1469-0691.12363","article-title":"Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis","volume":"20","author":"Lemos","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/ice.2017.197","article-title":"Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis","volume":"38","author":"Kohler","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0065","first-page":"668","article-title":"Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis","volume":"72","author":"Righi","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0070","doi-asserted-by":"crossref","first-page":"11715","DOI":"10.1038\/srep11715","article-title":"Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis","volume":"25","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"issue":"10325","key":"10.1186\/s13613-023-01153-6_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0080","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00134-015-4138-x","article-title":"Understanding why resistant bacteria are associated with higher mortality in ICU patients","volume":"42","author":"Barbier","year":"2016","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review","volume":"27","author":"Palacios-Baena","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0090","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijantimicag.2018.08.026","article-title":"Carbapenems and alternative \u03b2-lactams for the treatment of infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance?","volume":"52","author":"Woerther","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13613-015-0061-0","article-title":"Mechanisms of antimicrobial resistance in Gram-negative bacilli","volume":"5","author":"Rupp\u00e9","year":"2015","journal-title":"Ann Intensive Care"},{"issue":"Suppl 7","key":"10.1186\/s13613-023-01153-6_bb0100","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01153-6_bb0105","doi-asserted-by":"crossref","first-page":"1075185","DOI":"10.3389\/fcimb.2022.1075185","article-title":"A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET)","volume":"12","author":"Hu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0115","volume":"3","author":"Sader","year":"2021","journal-title":"JAC Antimicrob Resist."},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0125","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01153-6_bb0130","unstructured":"European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacteriaceae : second update, 26 September 2019. www.ecdc.europa.eu. Accessed 15 Jan 2023."},{"key":"10.1186\/s13613-023-01153-6_bb0135","unstructured":"Jousset A, Emeraud C, Bonnin RA, Naas T, Dortet L. Caract\u00e9ristiques et \u00e9volution des souches d\u2019ent\u00e9robact\u00e9ries productrices de carbap\u00e9n\u00e9mases (EPC) isol\u00e9es en France, 2012\u20132020. Bull Epid\u00e9miol Hebd. 18\u201319:351\u20138."},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0140","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/jac\/dkac289","article-title":"Faecal carriage of multidrug-resistant bacteria and associated risk factors: results from a point prevalence study","volume":"77","author":"Grohs","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0145","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkac122","article-title":"Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial","volume":"77","author":"Torrens","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0150","doi-asserted-by":"crossref","first-page":"e02384","DOI":"10.1128\/mBio.02384-19","article-title":"High-risk international clones of carbapenem-nonsusceptible Pseudomonas aeruginosa endemic to Indonesian intensive care units: impact of a multifaceted infection control intervention analyzed at the genomic level","volume":"10","author":"Pelegrin","year":"2019","journal-title":"MBio"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jinf.2019.10.021","article-title":"Ventilator-associated pneumonia due to Stenotrophomonas maltophilia: risk factors and outcome","volume":"80","author":"Ibn Saied","year":"2020","journal-title":"J Infect"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0160","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/s13613-023-01153-6_bb0165","first-page":"1","article-title":"Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates","volume":"13","author":"Tamma","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0170","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012\u201315","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0175","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1128\/AAC.00107-16","article-title":"Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0180","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkab306","article-title":"Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime\/avibactam, meropenem\/vaborbactam and comparators against these isolates","volume":"76","author":"Castanheira","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0185","doi-asserted-by":"crossref","first-page":"516.e1","DOI":"10.1016\/j.cmi.2019.11.011","article-title":"Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam: epidemiology and genomic characterization","volume":"26","author":"Gaibani","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0190","doi-asserted-by":"crossref","first-page":"e01816","DOI":"10.1128\/AAC.01816-19","article-title":"Ceftazidime-avibactam resistance associated with increased blaKPC-3 gene copy number mediated by pKpQIL plasmid derivatives in sequence type 258 Klebsiella pneumoniae","volume":"64","author":"Coppi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0195","doi-asserted-by":"crossref","first-page":"e00642","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01111-19","article-title":"Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity","volume":"63","author":"Mueller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0205","first-page":"1012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing Gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiot Basel Switz"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0210","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105925","article-title":"In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","volume":"56","author":"Tselepis","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0225","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/jac\/dkab252","article-title":"Activity of meropenem\/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014\u201319)","volume":"76","author":"Shortridge","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0235","doi-asserted-by":"crossref","first-page":"e00573","DOI":"10.1128\/AAC.00573-18","article-title":"Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae","volume":"62","author":"Gomez-Simmonds","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/mdr.2018.0065","article-title":"Effect of porins and blaKPC expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance?","volume":"24","author":"Balabanian","year":"2018","journal-title":"Microb Drug Resist"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0245","doi-asserted-by":"crossref","first-page":"e02048","DOI":"10.1128\/AAC.02048-18","article-title":"Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Wilson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0250","doi-asserted-by":"crossref","first-page":"e01936","DOI":"10.1128\/AAC.01936-19","article-title":"Potency of vaborbactam is less affected than that of avibactam in strains producing KPC-2 mutations that confer resistance to ceftazidime-avibactam","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0255","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist."},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0260","doi-asserted-by":"crossref","first-page":"e01582","DOI":"10.1128\/AAC.01582-20","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant Gram-negative bacteria","volume":"64","author":"Mushtaq","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0265","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/jac\/dkz226","article-title":"Inoculum effect of \u03b2-lactam antibiotics","volume":"74","author":"Lenhard","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0270","doi-asserted-by":"crossref","first-page":"1503.e1","DOI":"10.1016\/j.cmi.2022.06.018","article-title":"Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales","volume":"28","author":"Danjean","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0275","doi-asserted-by":"crossref","first-page":"e02125","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0280","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0285","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0290","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0295","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0300","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"Del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0305","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0315","doi-asserted-by":"crossref","first-page":"e01117","DOI":"10.1128\/AAC.01117-20","article-title":"Mechanisms of resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study","volume":"65","author":"Fournier","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0320","doi-asserted-by":"crossref","first-page":"e01045","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0325","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1093\/jac\/dkac298","article-title":"In vitro activity of imipenem\/relebactam against Pseudomonas aeruginosaisolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)","volume":"77","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0330","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jac\/dkz133","article-title":"Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections","volume":"74","author":"BSAC Resistance Surveillance Standing Committee","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0335","doi-asserted-by":"crossref","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0340","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jac\/dkv402","article-title":"In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria","volume":"71","author":"Ito","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0345","doi-asserted-by":"crossref","first-page":"e01801","DOI":"10.1128\/AAC.01801-18","article-title":"ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum \u03b2-lactamases and carbapenemases","volume":"63","author":"Jacobs","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0350","doi-asserted-by":"crossref","first-page":"447.e1","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106744","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020\u20132021)","volume":"61","author":"Sader","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0360","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0365","doi-asserted-by":"crossref","first-page":"652.e1","DOI":"10.1016\/j.cmi.2022.12.021","article-title":"Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol","volume":"29","author":"Devoos","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1186\/s13613-023-01153-6_bb0370","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints (available at www.eucast.org\/clinical_breakpoints. Accessed 23 May 2023."},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0375","doi-asserted-by":"crossref","first-page":"e00010","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-\u03b2-lactamase-producing Gram-negative bacteria","volume":"63","author":"Emeraud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0380","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/mdr.2021.0389","article-title":"In vitro comparison of aztreonam\/amoxicillin-clavulanate versus aztreonam\/ceftazidime-avibactam on ceftazidime-avibactam resistantStenotrophomonas maltophilia","volume":"28","author":"Cr\u00e9met","year":"2022","journal-title":"Microb Drug Resist"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0385","doi-asserted-by":"crossref","first-page":"e00160","DOI":"10.1128\/AAC.00160-19","article-title":"Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum \u03b2-lactamases from U.S. hospitals","volume":"63","author":"Castanheira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0390","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/1120009X.2022.2031471","article-title":"Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019\u20132021): emergence of complex resistance phenotypes","volume":"34","author":"Bianco","year":"2022","journal-title":"J Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0395","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1128\/AAC.02253-13","article-title":"Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates","volume":"58","author":"Snydman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0400","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.01964-15","article-title":"In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study","volume":"60","author":"Armstrong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0405","doi-asserted-by":"crossref","first-page":"e02584","DOI":"10.1128\/AAC.02584-17","article-title":"In vitro activity of ceftazidime-avibactam against isolates from patients in a phase 3 clinical trial for treatment of complicated intra-abdominal infections","volume":"62","author":"Stone","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0410","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0415","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0420","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"9981","key":"10.1186\/s13613-023-01153-6_bb0425","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0430","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0435","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0440","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0445","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0450","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0455","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2666-5247(21)00271-8","article-title":"Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?","volume":"2","author":"Choby","year":"2021","journal-title":"Lancet Microbe"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0460","doi-asserted-by":"crossref","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","article-title":"US Food and Drug Administration (FDA): benefit-risk considerations for Cefiderocol (Fetroja\u00ae)","volume":"72","author":"Naseer","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0465","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa651","article-title":"Meta-analysis of clinical outcomes using ceftazidime\/avibactam, ceftolozane\/tazobactam, and meropenem\/vaborbactam for the treatment of multidrug-resistant Gram-negative infections","volume":"8","author":"Wilson","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0470","doi-asserted-by":"crossref","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0475","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s13613-023-01153-6_bb0480","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.2147\/IDR.S369368","article-title":"Ceftazidime-avibactam as salvage therapy in pediatric liver transplantation patients with infections caused by carbapenem-resistant Enterobacterales","volume":"15","author":"Wang","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0490","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0495","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0500","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0505","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jac\/dkac049","article-title":"Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)","volume":"77","author":"Cast\u00f3n","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106536","article-title":"Multicentre study of ceftazidime\/avibactam for Gram-negative bacteria infections in critically ill patients","volume":"59","author":"Baland\u00edn","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0515","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac022","article-title":"Compassionate use of meropenem\/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study","volume":"4","author":"Tumbarello","year":"2022","journal-title":"JAC Antimicrob Resist."},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0520","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-world, multicenter experience with meropenem-vaborbactam for Gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0525","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0530","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0535","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0540","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01100-22","article-title":"Evidence for efficacy of cefiderocol against OXA-48-containing isolates from the APEKS-NP and CREDIBLE-CR trials","volume":"66","author":"Longshaw","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0545","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant Enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0550","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0555","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0560","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00751-22","article-title":"Ceftazidime-avibactam plus aztreonam for the treatment of infections by VIM-type-producing Gram-negative bacteria","volume":"66","author":"Sempere","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0565","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0570","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-Tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0575","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.idnow.2021.05.003","article-title":"Real-world evaluation of ceftolozane\/tazobactam therapy and clinical outcomes in France","volume":"51","author":"Castan","year":"2021","journal-title":"Infect Dis Now"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0580","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0585","article-title":"A multicenter evaluation of ceftolozane\/tazobactam treatment outcomes in immunocompromised patients with multidrug-resistant Pseudomonas aeruginosa infections","volume":"8","author":"C\/T Alliance to deliver Real-world Evidence (CARE)","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106270","article-title":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","volume":"57","author":"Balandin","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01153-6_bb0600","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus Polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1186\/s13613-023-01153-6_bb0605","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0610","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ijantimicag.2018.01.016","article-title":"Clinical experience with ceftazidime\/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae","volume":"51","author":"Santevecchi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0615","first-page":"640","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for multidrug-resistant Gram-negative infections in immunocompetent patients: a single-center retrospective study","volume":"9","author":"Cultrera","year":"2020","journal-title":"Antibiot Basel Switz"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0620","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0625","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0630","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00134-019-05520-5","article-title":"Rationalizing antimicrobial therapy in the ICU: a narrative review","volume":"45","author":"Timsit","year":"2019","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0635","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0640","first-page":"388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiot Basel Switz"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0645","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniaeinfections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0650","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac121","article-title":"Effect of ceftazidime\/avibactam plus fosfomycin combination on 30-day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study","volume":"4","author":"Oliva","year":"2022","journal-title":"JAC Antimicrob Resist."},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0655","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2016.11.005","article-title":"Clinical experience with ceftazidime\/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Xipell","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0660","first-page":"79","article-title":"Ceftolozane-tazobactam combination therapy compared to ceftolozane-tazobactam monotherapy for the treatment of severe infections: a systematic review and meta-analysis","volume":"10","author":"Fiore","year":"2021","journal-title":"Antibiot Basel Switz"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0665","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jiph.2022.07.006","article-title":"Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?","volume":"15","author":"Corcione","year":"2022","journal-title":"J Infect Public Health"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0670","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0675","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","article-title":"Management of carbapenem-resistant Enterobacteriaceae infections","volume":"25","author":"Durante-Mangoni","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0680","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","article-title":"Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients","volume":"75","author":"Al-Shaer","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0685","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0690","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","article-title":"Therapeutic drug monitoring of antibiotics: defining the therapeutic range","volume":"44","author":"Abdul-Aziz","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0695","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0700","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0705","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","article-title":"Cefepime free minimum concentration to minimum inhibitory concentration (fCmin\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia","volume":"45","author":"Aitken","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-023-01153-6_bb0710","first-page":"63","article-title":"Killing and regrowth of bacteria in vitro: a review","volume":"74","author":"Craig","year":"1990","journal-title":"Scand J Infect Dis Suppl"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0715","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0720","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","article-title":"Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa","volume":"49","author":"Tam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0725","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","article-title":"Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa","volume":"38","author":"Pilmis","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0730","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","article-title":"First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis","volume":"35","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0735","article-title":"Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections","volume":"2013","author":"Shiu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0740","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0745","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/jac\/dkx221","article-title":"Determination of alternative ceftolozane\/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg\/L","volume":"72","author":"Natesan","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0750","first-page":"993","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of novel \u03b2-lactam\/\u03b2-lactamase inhibitors against Gram-negative bacterial in critically ill patients","volume":"10","author":"Han","year":"2021","journal-title":"Antibiot Basel Switz"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0755","first-page":"1739","volume":"11","author":"Gatti","year":"2022","journal-title":"Antibiot Basel Switz"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0760","doi-asserted-by":"crossref","first-page":"e01381","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function","volume":"61","author":"Katsube","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0765","first-page":"458","article-title":"Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiot Basel Switz"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0770","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clinthera.2020.01.021","article-title":"Assessment of meropenem and vaborbactam room temperature and refrigerated stability in polyvinyl chloride bags and elastomeric devices","volume":"42","author":"Chen","year":"2020","journal-title":"Clin Ther"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb0775","first-page":"546","article-title":"Drug regimens of novel antibiotics in critically ill patients with varying renal functions: a rapid review","volume":"11","author":"Gorham","year":"2022","journal-title":"Antibiot Basel Switz"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0780","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: are we jumping the gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0785","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Crit Care Explor"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0790","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0795","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cmi.2020.11.032","article-title":"Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review","volume":"27","author":"de Vroom","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0800","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1603017","article-title":"Initiation strategies for renal-replacement therapy in the intensive care unit","volume":"375","author":"Gaudry","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106113","article-title":"What is the optimal loading dose of broad-spectrum \u03b2-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling","volume":"56","author":"Delattre","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0810","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-021-01040-y","article-title":"Antimicrobial dose reduction in continuous renal replacement therapy: myth or real need? A practical approach for guiding dose optimization of novel antibiotics","volume":"60","author":"Gatti","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0815","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1086\/499535","article-title":"Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information","volume":"42","author":"Scheetz","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0820","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13054-019-2434-5","article-title":"Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration","volume":"23","author":"Aguilar","year":"2019","journal-title":"Crit Care"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0825","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy","volume":"61","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0830","doi-asserted-by":"crossref","first-page":"e01306","DOI":"10.1128\/AAC.01306-18","article-title":"Ex vivo characterization of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam","volume":"62","author":"Sime","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0835","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/phar.2023","article-title":"Comprehensive guidance for antibiotic dosing in obese adults","volume":"37","author":"Meng","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0840","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.01083-12","article-title":"Case-control study of drug monitoring of \u03b2-lactams in obese critically ill patients","volume":"57","author":"Hites","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0845","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0850","doi-asserted-by":"crossref","first-page":"e02131","DOI":"10.1128\/AAC.02131-18","article-title":"Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation in a lung transplant recipient","volume":"63","author":"Arena","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0855","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0267659119864813","article-title":"Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane","volume":"35","author":"Argudo","year":"2020","journal-title":"Perfusion"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0860","first-page":"649","article-title":"Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance","volume":"10","author":"K\u00f6nig","year":"2021","journal-title":"Antibiot Basel Switz"},{"key":"10.1186\/s13613-023-01153-6_bb0865","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0870","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0875","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb0880","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10096-020-04149-3","article-title":"Serious adverse events with novel beta-lactam\/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis","volume":"40","author":"Gatti","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0885","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-lactams toxicity in the intensive care init: an underestimated collateral damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0890","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijantimicag.2015.02.027","article-title":"Ecological effect of ceftazidime\/avibactam on the normal human intestinal microbiota","volume":"46","author":"Rashid","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0895","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00134-018-5309-3","article-title":"The gut microbiota of critically ill patients: first steps in an unexplored world","volume":"44","author":"Rupp\u00e9","year":"2018","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0900","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","article-title":"Resistance to novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: the \u2018price of progress","volume":"34","author":"Papp-Wallace","year":"2020","journal-title":"Infect Dis Clin North Am"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0905","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0910","doi-asserted-by":"crossref","first-page":"e02097","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0915","doi-asserted-by":"crossref","first-page":"e02101","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0920","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/jac\/dkz330","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo","volume":"74","author":"G\u00f6ttig","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0925","doi-asserted-by":"crossref","first-page":"124.e1","DOI":"10.1016\/j.cmi.2019.08.020","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb0930","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106278","article-title":"Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)","volume":"57","author":"Johnson","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0940","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/cid\/ciac097","article-title":"Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia","volume":"75","author":"Shields","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb0945","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1164\/rccm.201609-1848OC","article-title":"The timing of early antibiotics and hospital mortality in sepsis","volume":"196","author":"Liu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1186\/s13613-023-01153-6_bb0950","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency care for sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb0955","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00134-020-05929-3","article-title":"Antimicrobial-associated harm in critical care: a narrative review","volume":"46","author":"Arulkumaran","year":"2020","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb0960","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2899","article-title":"Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use","volume":"3","author":"Rhee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb0965","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1473-3099(12)70151-2","article-title":"Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study","volume":"12","author":"Hranjec","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0970","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb0975","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb0980","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhin.2016.05.018","article-title":"Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers","volume":"94","author":"Dickstein","year":"2016","journal-title":"J Hosp Infect"},{"issue":"Suppl 2","key":"10.1186\/s13613-023-01153-6_bb0985","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/infdis\/jiz622","article-title":"The colonization of carbapenem-resistant Klebsiella pneumoniae: epidemiology, resistance mechanisms, and risk factors in patients admitted to intensive care units in China","volume":"221","author":"Qin","year":"2020","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb0990","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035893","article-title":"Risk factor for intestinal carriage of carbapenem-resistant Acinetobacter baumannii and the impact on subsequent infection among patients in an intensive care unit: an observational study","volume":"10","author":"Qiao","year":"2020","journal-title":"BMJ Open"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb0995","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/cid\/ciac354","article-title":"Impact of a rapid molecular test for Klebsiella pneumoniae carbapenemase and ceftazidime-avibactam use on outcomes after bacteremia caused by carbapenem-resistant Enterobacterales","volume":"75","author":"Satlin","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb1000","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/cid\/ciy801","article-title":"Rapid molecular diagnostics to inform empiric use of ceftazidime\/avibactam and ceftolozane\/tazobactam against Pseudomonas aeruginosa: PRIMERS IV","volume":"68","author":"Evans","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1005","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1010","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1020","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb1025","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb1035","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb1045","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1050","doi-asserted-by":"crossref","first-page":"e01052","DOI":"10.1128\/AAC.01052-20","article-title":"Is ceftazidime\/avibactam an option for serious infections due to extended-spectrum-\u03b2-lactamase- and AmpC-producing enterobacterales?: a systematic review and meta-analysis","volume":"65","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1055","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/s13613-023-01153-6_bb1060","unstructured":"SPIADI Network. National surveillance of device-associated infection, France, 2021. www.spiadi.fr. Accessed 1 Mar 2023."},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb1065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40268-018-0241-0","article-title":"Population pharmacokinetic modelling of ceftazidime and avibactam in the plasma and epithelial lining fluid of healthy volunteers","volume":"18","author":"Dimelow","year":"2018","journal-title":"Drugs RD"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/sur.2018.141","article-title":"Pharmacokinetic and pharmacodynamic analysis of ceftazidime\/avibactam in critically ill patients","volume":"20","author":"Stein","year":"2019","journal-title":"Surg Infect"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb1075","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00134-004-2171-2","article-title":"Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia","volume":"30","author":"Boselli","year":"2004","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb1085","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1128\/AAC.04232-14","article-title":"Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia","volume":"59","author":"Cousson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb1090","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02104-21","article-title":"Pharmacokinetic\/pharmacodynamic simulations of cost-effective dosage regimens of ceftolozane-tazobactam and ceftazidime-avibactam in patients with renal impairment","volume":"66","author":"Dheyriat","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1095","doi-asserted-by":"crossref","first-page":"e02446","DOI":"10.1128\/AAC.02446-17","article-title":"Avibactam pharmacokinetic\/pharmacodynamic targets","volume":"62","author":"Nichols","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb1100","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa349","article-title":"Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with ceftazidime\/avibactam","volume":"7","author":"Yasmin","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1105","doi-asserted-by":"crossref","first-page":"e01655","DOI":"10.1128\/AAC.01655-19","article-title":"A population pharmacokinetic model-guided evaluation of ceftolozane-tazobactam dosing in critically ill patients undergoing continuous venovenous hemodiafiltration","volume":"64","author":"Sime","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1120","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","article-title":"Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3 g of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia","volume":"75","author":"Caro","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb1125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jiac.2018.11.005","article-title":"Population pharmacokinetics of tazobactam\/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection","volume":"25","author":"Kakara","year":"2019","journal-title":"J Infect Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1130","doi-asserted-by":"crossref","first-page":"e01698","DOI":"10.1128\/AAC.01698-20","article-title":"Cerebrospinal fluid penetration of ceftolozane-tazobactam in critically Iill patients with an indwelling external ventricular drain","volume":"65","author":"Sime","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb1135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12462","article-title":"Population pharmacokinetic analysis for imipenem-relebactam in healthy volunteers and patients with bacterial infections","volume":"8","author":"Bhagunde","year":"2019","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb1140","doi-asserted-by":"crossref","first-page":"e00280","DOI":"10.1128\/AAC.00280-18","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a \u03b2-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants","volume":"62","author":"Rhee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb1145","first-page":"1184","article-title":"Imipenem\/relebactam ex vivo clearance during continuous renal replacement therapy","volume":"10","author":"Jang","year":"2021","journal-title":"Antibiot Basel Switz"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1150","doi-asserted-by":"crossref","first-page":"e02323","DOI":"10.1128\/AAC.02323-17","article-title":"Exploring the pharmacokinetic\/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1155","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bcp.12435","article-title":"Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens","volume":"78","author":"Couffignal","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb1160","doi-asserted-by":"crossref","first-page":"e02103","DOI":"10.1128\/AAC.02103-17","article-title":"Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment","volume":"62","author":"Rubino","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb1165","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/AAC.01713-15","article-title":"Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects","volume":"59","author":"Wenzler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb1170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40121-020-00344-z","article-title":"An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam","volume":"9","author":"Wenzler","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb1175","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/jac\/dkz103","article-title":"In vivo pharmacokinetic analysis of meropenem\/vaborbactam during continuous venovenous haemodialysis","volume":"74","author":"Kufel","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1186\/s13613-023-01153-6_bb1180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000086598","article-title":"Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment","volume":"51","author":"Kuti","year":"2005","journal-title":"Chemotherapy"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb1185","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/jcph.1595","article-title":"Evaluation of hemodialysis effect on pharmacokinetics of meropenem\/vaborbactam in end-stage renal disease patients using modeling and simulation","volume":"60","author":"Zhuang","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1190","doi-asserted-by":"crossref","first-page":"e01659","DOI":"10.1128\/AAC.01659-18","article-title":"Pharmacokinetics\/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem","volume":"63","author":"Griffith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/34.1.175","article-title":"Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges","volume":"34","author":"Dagan","year":"1994","journal-title":"J Antimicrob Chemother"},{"issue":"15","key":"10.1186\/s13613-023-01153-6_bb1200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2050-6511-15-21","article-title":"Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients","volume":"14","author":"Goncalves-Pereira","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"10.1186\/s13613-023-01153-6_bb1205","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13613-019-0622-8","article-title":"Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria","volume":"10","author":"Kothekar","year":"2020","journal-title":"Ann Intensive Care"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb1210","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/jac\/dkw231","article-title":"A review of the pharmacokinetics and pharmacodynamics of aztreonam","volume":"71","author":"Ramsey","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb1215","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/jac\/dkv132","article-title":"Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam","volume":"70","author":"Singh","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb1220","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.29.2.281","article-title":"Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis","volume":"29","author":"Modai","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1186\/s13613-023-01153-6_bb1225","doi-asserted-by":"crossref","first-page":"e01391","DOI":"10.1128\/AAC.01391-17","article-title":"Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis","volume":"62","author":"Kawaguchi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1186\/s13613-023-01153-6_bb1230","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1186\/s13613-023-01153-6_bb1235","doi-asserted-by":"crossref","first-page":"e02163","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1186\/s13613-023-01153-6_bb1240","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1186\/s13613-023-01153-6_bb1245","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefiderocol","volume":"60","author":"Bilal","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1186\/s13613-023-01153-6_bb1250","doi-asserted-by":"crossref","first-page":"e02031","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1186\/s13613-023-01153-6_bb1255","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Luque-Paz","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1186\/s13613-023-01153-6_bb1260","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1186\/s13613-023-01153-6_bb1265","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ofid\/ofac391","article-title":"Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa ventriculitis using cefiderocol: a case-report and literature review","volume":"9","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1186\/s13613-023-01153-6_bb1270","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-023-01153-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025004777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025004777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-023-01153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:40:31Z","timestamp":1776670831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025004777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":253,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2110582025004777"],"URL":"https:\/\/doi.org\/10.1186\/s13613-023-01153-6","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-023-01153-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s) 2023. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"65"}}